<DOC>
	<DOC>NCT02042599</DOC>
	<brief_summary>Describing a pharmacokinetic model of 48-h sevoflurane sedation in ICU patients with acute kidney failure</brief_summary>
	<brief_title>Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in ICU Patients With Acute Kidney Injury</brief_title>
	<detailed_description>Prospective clinical monocentric study in ICU with sedated ventilated patients (presenting acute kidney failure) with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sevoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)</detailed_description>
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Adult patients ventilated more than 48 h Stable respiratory and hemodynamic conditions Consent of patients or family Arterial line AKIN score = 3 BMI &lt;30 Sevoflurane anaphylaxia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sevoflurane</keyword>
	<keyword>Acute kidney injury</keyword>
	<keyword>Sedation</keyword>
	<keyword>ICU patients</keyword>
</DOC>